鉴定新型triazole-pyrazol结合物作为潜在的抗剂:合成和生物评估
Wagdy M Eldehna1, Mahmoud Abdelrahman Alkabbani2, Zainab M Elsayed3
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, P.O. Box 33516, Kafrelsheikh 33516, Egypt.
ACS chemical neuroscience
|July 28, 2025
概括
新的化合物7a和11a对有显著的抗活性. 这些有前途的候选药物有效地减少了发作,并在临床前模型中证明了安全性,为改善治疗提供了希望.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 仍然是一个复杂的神经系统疾病,需要新的有效治疗策略.
- 目前的治疗方法有局限性,需要开发新的抗药物.
研究的目的:
- 评估新合成的化合物 (7a-f和11a-c) 的抗潜力.
- 确定治疗中临床前开发的领先候选人.
主要方法:
- 在动物中使用乙 (PTZ) 和皮洛卡 (PIL) 诱导的发作模型.
- 评估了抗活性,神经保护和安全性.
- 进行生物化学分析以调查作用机制,包括氧化应激和神经炎症.
主要成果:
- 化合物7a和11a在PTZ和PIL模型中都表现出显著的抗发作保护.
- 这两种化合物都在延迟发作,减少严重程度和改善生存率方面表现出有效性.
- 生物化学分析显示,7a 和 11a 减少了氧化应激,神经炎症,质激活和海马刺激毒性.
- 化合物7a在评估的参数中表现优于酸,而11a在降低星细胞激活 (GFAP) 中表现出相似的有效性.
- 毒理学评估证实了7a和11a化合物的安全性,没有观察到对主要器官的不良影响.
结论:
- 化合物7a和11a是强效和安全的抗药剂,在治疗中具有显著的潜力.
- 这些化合物表现出多功能机制,针对的关键病理途径.
- 根据它们有前途的疗效和安全性,需要对7a和11a进行进一步的临床前开发.
相关概念视频
01:11Aryldiazonium Salts to Azo Dyes: Diazo Coupling
3.2K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
3.2K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
01:14Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
01:28Inhibitors of Bacterial DNA Synthesis
128
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
128